Stock ADAP ADAPTIMMUNE THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Adaptimmune Therapeutics plc

Equities

ADAP

US00653A1079

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
1.075 USD +1.42% Intraday chart for Adaptimmune Therapeutics plc +10.06% +35.56%
04-24 European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
04-23 European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading MT

Evolution of the average Target Price on Adaptimmune Therapeutics plc

Price target over the last 5 years

History of analyst recommendation changes

25.YUffx9B8QeUCP0WXSKv1huSPB0p8kvYrWeNc-2yCEfQ.VHeqoLskJqlDfHW6JsGzzYW2cXMT9MNJM6gPqybkU50Zf4yuvwUT1VJJcQ~b41c0068fd4defb64263bdba72cf8517

Analyst Recommendations on Adaptimmune Therapeutics plc

Barclays Adjusts Adaptimmune Therapeutics Price Target to $1 From $2, Maintains Underweight Rating MT
EF Hutton Initiates Adaptimmune Therapeutics at Buy With $10 Price Target MT
Guggenheim Upgrades Adaptimmune Therapeutics to Buy From Neutral, Price Target is $5 MT
Wells Fargo Adjusts Price Target on Adaptimmune Therapeutics to $3 From $1.50, Maintains Equal-Weight Rating MT
Mizuho Upgrades Adaptimmune Therapeutics to Buy From Neutral, Price Target is $9 MT
SVB Leerink Adjusts Adaptimmune Therapeutics' Price Target to $3 from $7, Keeps Market Perform Rating MT
Barclays Cuts Price Target for Adaptimmune Therapeutics to $2 From $4, Maintains Underweight Rating MT
ADAPTIMMUNE THERAPEUTICS : Wells Fargo Adjusts Price Target on Adaptimmune Therapeutics to $7 From $6, Maintains Equal-Weight Rating MT
ADAPTIMMUNE THERAPEUTICS : SVB Leerink Adjusts Adaptimmune Therapeutics PT to $7 From $6, Maintains Market Perform Rating MT
Adaptimmune Therapeutics plc Announces Clinical Responses Across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation Surpass Trial CI
ADAPTIMMUNE THERAPEUTICS : SVB Leerink Adjusts Adaptimmune Therapeutics' Price Target to $6 from $5, Keeps Market Perform Rating MT
ADAPTIMMUNE THERAPEUTICS : Barclays Starts Adaptimmune Therapeutics at Underweight With $4 Price Target MT
ADAPTIMMUNE THERAPEUTICS : SVB Leerung Adjusts Adaptimmune Therapeutics PT to $6 From $10, Maintains Market Perform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.075 USD
Average target price
3.6 USD
Spread / Average Target
+234.88%
High Price Target
9 USD
Spread / Highest target
+737.21%
Low Price Target
1 USD
Spread / Lowest Target
-6.98%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Adaptimmune Therapeutics plc

Barclays
EF Hutton
Guggenheim
Wells Fargo Securities
Mizuho Securities
SVB Leerink

Ratings for Adaptimmune Therapeutics plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ADAP Stock
  4. Consensus Adaptimmune Therapeutics plc